Janssen:Janssen - European Commission Has Granted Marketing Authorisation For Expanded Use Of Darzalex Subcutaneous Formulation In Two New Indications.Janssen - Darzalex Sc Formulation Becomes First Approved Treatment For Newly Diagnosed Systemic Light Chain Amyloidosis In Europe.Janssen - Darzalex Sc Formulation Gains An Additional Approval In Pre-Treated Multiple Myeloma.
精彩评论